Endometrial cancer stands as the most frequently diagnosed gynecologic malignancy in developed countries—a cancer that often announces its presence early through abnormal bleeding, leading to relatively favorable outcomes for most women. Imagine the endometrium, the dynamic lining of the uterus that cycles monthly with hormonal changes, occasionally accumulating genetic alterations that transform normal cells into malignant ones. Unlike ovarian cancer's silent progression, endometrial cancer typically declares itself through postmenopausal bleeding or abnormal premenopausal bleeding, creating a built-in early warning system. However, beneath this generally favorable prognosis lies molecular complexity, with distinct subtypes ranging from indolent estrogen-driven tumors to aggressive variants that defy conventional treatments. Understanding this spectrum—from prevention through molecular classification to personalized treatment—is essential for optimizing outcomes across all endometrial cancer subtypes.
🔄 Dual Pathway Carcinogenesis
Endometrial cancer develops through two distinct pathways: estrogen-driven (Type I) and non-estrogen-related (Type II), each with different risk factors, molecular profiles, and clinical behaviors.
Type I (Endometrioid)
80-85% of cases
Estrogen-driven
Favorable prognosis
Type II (Non-endometrioid)
10-15% of cases
Estrogen-independent
Aggressive behavior
Epidemiology
- Incidence: Most common gynecologic cancer
- New cases: ~66,000 annually in US
- Lifetime risk: 1 in 35 women (2.8%)
- Mortality: ~12,000 deaths annually
- Age: Median diagnosis 63 years
- Survival: 81% 5-year overall
Risk Factors
- Hormonal: Unopposed estrogen, tamoxifen
- Metabolic: Obesity, diabetes, hypertension
- Reproductive: Nulliparity, late menopause
- Genetic: Lynch syndrome, Cowden syndrome
- Protective: OCPs, multiparity, smoking
🔬 Histologic Subtypes & Molecular Features
Endometrial cancer encompasses diverse histologic subtypes with distinct molecular alterations, clinical behaviors, and treatment responses.
Type I Subtypes
- Endometrioid: G1-G3, PTEN mutations
- Villoglandular: Exophytic growth pattern
- Secretory: Progesterone effects
- Ciliated: Rare variant
- Molecular: PTEN, PIK3CA, KRAS, CTNNB1
Type II Subtypes
- Serous: TP53 mutations, aggressive
- Clear cell: HNF1B, ARID1A mutations
- Carcinosarcoma: Biphasic, very aggressive
- Undifferentiated: Poorly differentiated
- Molecular: TP53, PPP2R1A, FBXW7
TCGA Molecular Groups
- POLE-ultramutated: Excellent prognosis MSI-hypermutated: Lynch syndrome associated
- Copy-number low: Intermediate prognosis
- Copy-number high: Serous-like, poor prognosis
- Clinical utility: Guides adjuvant therapy
Histologic Subtypes and Characteristics
| Subtype | Frequency | Typical Grade | Key Molecular Features | 5-Year Survival (Stage I) |
|---|---|---|---|---|
| Endometrioid G1 | 55-60% | Low | PTEN, PIK3CA, KRAS, ARID1A mutations | 90-95% |
| Endometrioid G2 | 15-20% | Intermediate | Similar to G1 with more complexity | 85-90% |
| Endometrioid G3 | 5-10% | High | TP53 mutations in 50%, more aggressive | 70-80% |
| Serous | 5-10% | High | TP53 mutations (>90%), HER2 amplification | 50-60% |
| Clear Cell | 2-4% | High | ARID1A, PIK3CA, HNF1B mutations | 60-70% |
| Carcinosarcoma | 2-5% | High | TP53, PIK3CA, similar to serous | 40-50% |
🎯 Clinical Presentation & Diagnosis
Endometrial cancer typically presents with abnormal uterine bleeding, allowing for relatively early diagnosis in most cases. The diagnostic pathway focuses on endometrial tissue sampling.
Presenting Symptoms
- Postmenopausal bleeding: 90% of cases
- Abnormal premenopausal bleeding: Heavy, intermenstrual
- Pyometra: Infected uterine contents
- Advanced disease: Pain, bloating, weight loss
- Asymptomatic: Incidental finding (rare)
Diagnostic Evaluation
- Endometrial biopsy: Office-based, 90% accurate
- Dilation & curettage: Higher accuracy
- Transvaginal ultrasound: Endometrial thickness
- Hysteroscopy: Direct visualization
- Imaging: MRI for local staging, CT for advanced
Evaluation of Postmenopausal Bleeding
| Initial Test | Sensitivity | Specificity | Advantages | Limitations |
|---|---|---|---|---|
| Endometrial Biopsy | 90-98% | 98-100% | Office procedure, immediate diagnosis, cost-effective | May miss focal lesions, discomfort, cervical stenosis |
| Transvaginal Ultrasound | 95% | 60% | Non-invasive, assesses other pelvic pathology | Low specificity, cannot distinguish hyperplasia from cancer |
| Saline Infusion Sonohysterography | 95% | 85% | Better detection of polyps, submucosal fibroids | More invasive, requires technical expertise |
| Hysteroscopy with Biopsy | 99% | 95% | Gold standard, direct visualization, therapeutic potential | Requires anesthesia in OR, cost, overdiagnosis risk |
💊 Staging & Surgical Management
Comprehensive surgical staging provides prognostic information and guides adjuvant therapy. The FIGO 2009 staging system incorporates histologic grade and depth of invasion.
Surgical Principles
- Total hysterectomy: Removal of uterus and cervix
- Bilateral salpingo-oophorectomy: Remove tubes/ovaries
- Lymph node assessment: Sentinel or systematic
- Omentectomy: For serous/clear cell types
- Cytoreduction: For advanced disease
Sentinel Lymph Node Mapping
- Technique: Cervical injection of tracer
- Detection rate: 85-95%
- Accuracy: 97% for detecting metastasis
- Advantages: Reduced morbidity, targeted sampling
- Indications: Apparent early-stage disease
Fertility Preservation
- Candidates: Grade 1 endometrioid, no myoinvasion
- Options: Progestin therapy, LNG-IUD
- Monitoring: Repeat sampling every 3-6 months
- Success rates: 70-80% initial response
- Definitive surgery: After childbearing completed
FIGO 2009 Staging System
| Stage | Description | Primary Treatment | 5-Year Survival | Adjuvant Therapy |
|---|---|---|---|---|
| IA | No or <50% myometrial invasion, Grade 1-2 | Surgery alone | 90-95% | None recommended |
| IB | ≥50% myometrial invasion, Grade 1-2 | Surgery ± vaginal brachytherapy | 85-90% | Consider vaginal cuff brachytherapy |
| II | Cervical stromal invasion | Radical hysterectomy or simple hysterectomy + radiation | 75-80% | Pelvic radiation ± chemotherapy |
| IIIA | Serosal/adnexal involvement | Maximal cytoreduction | 50-60% | Chemotherapy ± radiation |
| IIIB | Vaginal/parametrial involvement | Maximal cytoreduction | 40-50% | Chemotherapy + radiation |
| IIIC | Pelvic/para-aortic nodes | Lymphadenectomy + cytoreduction | 40-70% | Chemotherapy ± radiation |
| IV | Bladder/bowel invasion or distant metastasis | Cytoreduction if possible | 15-20% | Systemic therapy ± palliative radiation |
⚠️ Adjuvant Therapy & Advanced Disease
Adjuvant treatment decisions integrate stage, histology, grade, molecular features, and patient factors. Advanced and recurrent disease require systemic therapy approaches.
Adjuvant Therapy Indications
- Low-risk: Stage IA, G1-2 - observation
- Intermediate-risk: Stage IB, G1-2 - consider brachytherapy
- High-intermediate risk: PORTEC-2 criteria - brachytherapy
- High-risk: Stage I G3, Stage II - chemoradiation
- Advanced stage: Chemotherapy ± radiation
Systemic Therapy Options
- Carboplatin/paclitaxel: First-line standard
- Doxorubicin/cisplatin: Alternative regimen
- Hormonal therapy: Progestins, aromatase inhibitors
- Immunotherapy: Pembrolizumab for MSI-H/dMMR
- Targeted therapy: Lenvatinib + pembrolizumab
Treatment Selection Based on Risk Category
| Risk Category | Definition | Recurrence Risk | Recommended Adjuvant Therapy | Key Trials |
|---|---|---|---|---|
| Low | Stage IA, G1-2 endometrioid | 3-5% | Observation | GOG-99, ASTEC |
| Intermediate | Stage IB, G1-2 or Stage IA, G3 | 5-15% | Vaginal brachytherapy | PORTEC-2 |
| High-Intermediate | Age >60 + 2 risk factors* | 15-25% | Vaginal brachytherapy | PORTEC-1, GOG-99 |
| High | Stage I G3 with >50% invasion, Stage II | 25-40% | Chemotherapy + radiation | GOG-258, PORTEC-3 |
| Advanced | Stage III-IV | 50-80% | Chemotherapy ± radiation | GOG-122, GOG-184 |
🛡️ Prevention & Risk Reduction
Several strategies can reduce endometrial cancer risk, particularly for women with known risk factors or hereditary predisposition.
Pharmacologic Prevention
- Combined OCPs: 50% risk reduction
- Progestin-IUD: Local endometrial protection
- Metformin: Potential protective effect
- Aspirin: Possible modest risk reduction
- Weight loss: Significant risk reduction
Surveillance (High-risk)
- Lynch syndrome: Annual endometrial biopsy
- Tamoxifen users: Symptom-based evaluation
- Unopposed estrogen: Regular endometrial sampling
- Obesity: Low threshold for evaluation of symptoms
- Risk-reducing surgery: Hysterectomy for Lynch
Lifestyle Modifications
- Weight management: Most impactful intervention
- Physical activity: Regular exercise beneficial
- Diet: Mediterranean diet pattern
- Diabetes control: Optimal glycemic management
- Smoking cessation: Despite protective effect
🧠 Key Takeaways
- Most common gynecologic cancer: 66,000 new cases annually in US with generally favorable prognosis (81% 5-year survival)
- Dual pathway carcinogenesis: Type I (estrogen-driven, endometrioid, favorable) vs Type II (estrogen-independent, non-endometrioid, aggressive)
- Early symptom presentation: 90% present with abnormal uterine bleeding, facilitating early diagnosis
- Molecular classification: TCGA identifies four subgroups with prognostic and therapeutic implications
- Surgical foundation: Comprehensive staging with hysterectomy, BSO, and lymph node assessment
- Risk-adapted adjuvant therapy: Ranges from observation for low-risk to chemoradiation for high-risk disease
- Advanced disease treatment: Carboplatin/paclitaxel backbone with integration of immunotherapy for MSI-H tumors
- Prevention strategies: OCPs, weight management, and risk-reducing surgery for high-risk women
🧭 Conclusion
Endometrial cancer represents both a success story and an ongoing challenge in gynecologic oncology. The majority of women present with early-stage, low-grade disease and achieve excellent outcomes with surgery alone—a testament to the effectiveness of early detection through symptom recognition. However, the aggressive variants, particularly uterine serous carcinoma and high-grade endometrioid cancers, continue to pose significant therapeutic challenges and account for a disproportionate number of deaths. The evolving understanding of molecular subtypes is transforming endometrial cancer management, moving beyond traditional histology to incorporate genomic information that guides prognosis and treatment selection. From fertility preservation in young women with early disease to immunotherapy in mismatch repair-deficient advanced cancers, the field is advancing toward increasingly personalized approaches. As we continue to unravel the molecular complexity of this common malignancy, our goal remains optimizing outcomes for all women while minimizing treatment-related morbidity—ensuring that endometrial cancer's generally favorable statistics become a reality for every patient.
Endometrial cancer care exemplifies precision medicine—integrating traditional pathology with molecular wisdom to tailor treatment from fertility preservation to aggressive multimodality therapy, always guided by the principle of right treatment for the right patient at the right time.